RXi Acquires Apthera, Reorganizes To Support Late-Stage Breast Cancer Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Formerly focused on preclinical RNA interference compounds, the company installs a new CEO and takes possession of a cancer immunotherapy, the latest move away from RNAi by companies big and small.
You may also be interested in...
Capital Crunch Starting To Ease For Cancer Immunotherapy Space
A year later, biotech companies with cancer immunotherapies are beginning to reap the capital rewards of FDA's April 2010 approval of Dendreon's Provenge (sipuleucel-T) for prostate cancer.
Capital Crunch Starting To Ease For Cancer Immunotherapy Space
A year later, biotech companies with cancer immunotherapies are beginning to reap the capital rewards of FDA's April 2010 approval of Dendreon's Provenge (sipuleucel-T) for prostate cancer.
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.